cAMP-dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	B-protein
and	O
JunB	B-protein
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	B-protein
proteins	I-protein
.	O

We	O
demonstrate	O
that	O
JunD	B-protein
,	O
a	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
,	O
activates	O
transcription	O
of	O
the	O
human	B-DNA
proenkephalin	I-DNA
gene	I-DNA
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B-protein
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP-	B-DNA
,	I-DNA
phorbol	I-DNA
ester-	I-DNA
,	I-DNA
and	I-DNA
Ca	I-DNA
(	I-DNA
2+	I-DNA
)	I-DNA
-inducible	I-DNA
enhancer	I-DNA
,	O
and	O
JunD	B-protein
is	O
shown	O
to	O
bind	O
the	O
enhancer	B-DNA
as	O
a	O
homodimer	B-protein
.	O

Another	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
complex	I-protein
,	O
JunB	B-protein
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-protein
.	O

As	O
a	O
homodimer	O
JunB	B-protein
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	B-protein
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	B-protein
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
-dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	B-DNA
elements	I-DNA
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	B-protein
protein	I-protein
is	O
regulated	O
by	O
the	O
cAMP-dependent	O
second-messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-protein
and	O
other	O
AP-1-related	B-protein
proteins	I-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP-dependent	O
intracellular	O
signaling	O
pathways	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

88	NULL
,	NULL
pp	NULL
.	NULL

10222-10226	NULL
,	NULL
November	NULL
1991	NULL
Neurobiology	NULL
cAMP-dependent	NULL
regulation	NULL
of	NULL
proenkephalin	NULL
by	NULL
JunD	NULL
and	NULL
JunB	NULL
:	NULL
Positive	NULL
and	NULL
negative	NULL
effects	NULL
of	NULL
AP-1	NULL
proteins	NULL
(	NULL
opioid	NULL
/protein	NULL
kinase	NULL
A	NULL
/transcriptional	NULL
regulation	NULL
/second-messenger-inducible	NULL
enhancer	NULL
)	NULL
LinpaA	NULL
A.	NULL
KosiErskI1*	NULL
,	NULL
Hunc-Ming	NULL
CHu*	NULL
,	NULL
Y1	NULL
Tant	NULL
,	NULL
ano	NULL
MicHaEL	NULL
J.	NULL
Coms*t	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Neurobiology	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
,	NULL
Charlestown	NULL
,	NULL
MA	NULL
02129	NULL
;	NULL
and	NULL
*The	NULL
Program	NULL
in	NULL
Neuroscience	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02114	NULL
Communicated	NULL
by	NULL
Gerald	NULL
D.	NULL
Fischbach	NULL
,	NULL
August	NULL
14	NULL
,	NULL
1991	NULL
(	NULL
received	NULL
for	NULL
review	NULL
May	NULL
28	NULL
,	NULL
1991	NULL
)	NULL
ABSTRACT	NULL
We	NULL
demonstrate	NULL
that	NULL
JunD	NULL
,	NULL
a	NULL
component	NULL
of	NULL
the	NULL
AP-1	NULL
transcription	NULL
factor	NULL
complex	NULL
,	NULL
activates	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
proenkephalin	NULL
gene	NULL
in	NULL
a	NULL
fashion	NULL
that	NULL
is	NULL
completely	NULL
dependent	NULL
upon	NULL
the	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
,	NULL
protein	NULL
kinase	NULL
A.	NULL
Activation	NULL
of	NULL
proenkephalin	NULL
transcription	NULL
by	NULL
JunD	NULL
is	NULL
dependent	NULL
upon	NULL
a	NULL
previously	NULL
characterized	NULL
cAMP-	NULL
,	NULL
phorbol	NULL
ester-	NULL
,	NULL
and	NULL
Ca**-inducible	NULL
enhancer	NULL
,	NULL
and	NULL
JunD	NULL
is	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
enhancer	NULL
as	NULL
a	NULL
homodimer	NULL
.	NULL

Another	NULL
component	NULL
of	NULL
the	NULL
AP-1	NULL
transcription	NULL
complex	NULL
,	NULL
JunB	NULL
,	NULL
is	NULL
shown	NULL
to	NULL
inhibit	NULL
activation	NULL
mediated	NULL
by	NULL
JunD	NULL
.	NULL

As	NULL
a	NULL
homodimer	NULL
JunB	NULL
is	NULL
unable	NULL
to	NULL
bind	NULL
the	NULL
enhancer	NULL
;	NULL
however	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
c-Fos	NULL
,	NULL
high-affinity	NULL
binding	NULL
is	NULL
observed	NULL
.	NULL

Furthermore	NULL
,	NULL
JunD	NULL
is	NULL
shown	NULL
to	NULL
activate	NULL
transcription	NULL
of	NULL
genes	NULL
linked	NULL
to	NULL
both	NULL
cAMP	NULL
and	NULL
phorbol	NULL
ester	NULL
response	NULL
elements	NULL
in	NULL
a	NULL
protein	NULL
kinase	NULL
A-dependent	NULL
fashion	NULL
,	NULL
further	NULL
blurring	NULL
the	NULL
distinction	NULL
between	NULL
these	NULL
response	NULL
elements	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
an	NULL
AP-1l-related	NULL
protein	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
cAMP-dependent	NULL
second-messenger	NULL
pathway	NULL
and	NULL
suggest	NULL
that	NULL
JunD	NULL
and	NULL
other	NULL
AP-1-related	NULL
proteins	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
cAMP-dependent	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
.	NULL

In	NULL
the	NULL
nervous	NULL
system	NULL
,	NULL
signals	NULL
transmitted	NULL
across	NULL
synapses	NULL
are	NULL
known	NULL
to	NULL
regulate	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
postsynaptic	NULL
cell	NULL
(	NULL
1-5	NULL
)	NULL
.	NULL

This	NULL
process	NULL
involves	NULL
membrane	NULL
depolarization	NULL
and/or	NULL
the	NULL
binding	NULL
of	NULL
neurotransmitters	NULL
to	NULL
their	NULL
cell	NULL
surface	NULL
receptors	NULL
,	NULL
and	NULL
subsequent	NULL
signal	NULL
amplification	NULL
via	NULL
second-messenger	NULL
pathways	NULL
and	NULL
protein	NULL
kinases	NULL
.	NULL

Analysis	NULL
of	NULL
neural	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
has	NULL
focused	NULL
primarily	NULL
on	NULL
two	NULL
types	NULL
of	NULL
genes	NULL
:	NULL
the	NULL
immediate	NULL
early	NULL
genes	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
and	NULL
genes	NULL
encoding	NULL
peptide	NULL
neurotransmitters	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

Immediate	NULL
early	NULL
genes	NULL
are	NULL
thought	NULL
to	NULL
function	NULL
as	NULL
``	NULL
third	NULL
trans-ducing	NULL
neural	NULL
activity	NULL
into	NULL
long-term	NULL
changes	NULL
in	NULL
neural	NULL
functioning	NULL
by	NULL
activating	NULL
or	NULL
repressing	NULL
specific	NULL
target	NULL
genes-for	NULL
example	NULL
,	NULL
the	NULL
genes	NULL
encoding	NULL
peptide	NULL
neurotransmitters	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
opioid	NULL
precursor	NULL
proenkephalin	NULL
by	NULL
neural	NULL
activity	NULL
and	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
is	NULL
well	NULL
documented	NULL
(	NULL
6-11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

A	NULL
30-base-pair	NULL
(	NULL
bp	NULL
)	NULL
region	NULL
of	NULL
DNA	NULL
closely	NULL
linked	NULL
to	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
act	NULL
as	NULL
a	NULL
second-messenger-inducible	NULL
DNA	NULL
enhancer	NULL
that	NULL
regulates	NULL
transcription	NULL
of	NULL
this	NULL
gene	NULL
in	NULL
response	NULL
to	NULL
the	NULL
cAMP-	NULL
,	NULL
phorbol	NULL
ester-	NULL
,	NULL
and	NULL
Ca**+-dependent	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
(	NULL
13-16	NULL
)	NULL
.	NULL

Located	NULL
within	NULL
this	NULL
enhancer	NULL
are	NULL
two	NULL
adjacent	NULL
DNA	NULL
elements	NULL
called	NULL
cAMP	NULL
response	NULL
elements	NULL
(	NULL
CRE-1	NULL
and	NULL
CRE-2	NULL
)	NULL
,	NULL
which	NULL
act	NULL
cooperatively	NULL
to	NULL
regulate	NULL
proenkephalin	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
all	NULL
three	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
by	NULL
which	NULL
transcription	NULL
factors	NULL
mediate	NULL
cellular	NULL
responsiveness	NULL
to	NULL
second-messenger	NULL
pathways	NULL
are	NULL
in	NULL
most	NULL
cases	NULL
not	NULL
well	NULL
understood	NULL
;	NULL
however	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
cAMP-dependent	NULL
pathway	NULL
,	NULL
clearly	NULL
an	NULL
interesting	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

10222	NULL
and	NULL
complex	NULL
story	NULL
is	NULL
unfolding	NULL
.	NULL

The	NULL
activated	NULL
catalytic	NULL
subunit	NULL
of	NULL
the	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
(	NULL
protein	NULL
kinase	NULL
A	NULL
,	NULL
PKA	NULL
)	NULL
appears	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Further	NULL
evidence	NULL
supports	NULL
a	NULL
model	NULL
in	NULL
which	NULL
PKA	NULL
then	NULL
phosphorylates	NULL
a	NULL
single	NULL
residue	NULL
of	NULL
the	NULL
CRE-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
(	NULL
18	NULL
)	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
cAMP-dependent	NULL
activation	NULL
of	NULL
somatostatin	NULL
transcription	NULL
at	NULL
the	NULL
CRE	NULL
(	NULL
TGACGTCA	NULL
)	NULL
(	NULL
19	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
phosphorylation	NULL
by	NULL
other	NULL
kinases	NULL
at	NULL
sites	NULL
adjacent	NULL
to	NULL
the	NULL
CREB	NULL
PKA	NULL
site	NULL
also	NULL
plays	NULL
a	NULL
role	NULL
(	NULL
20	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
somatostatin	NULL
gene	NULL
,	NULL
where	NULL
a	NULL
single	NULL
element	NULL
is	NULL
sufficient	NULL
for	NULL
cAMP	NULL
regulation	NULL
(	NULL
19	NULL
)	NULL
,	NULL
analysis	NULL
in	NULL
our	NULL
laboratory	NULL
indicates	NULL
that	NULL
two	NULL
adjacent	NULL
and	NULL
closely	NULL
related	NULL
elements	NULL
are	NULL
necessary	NULL
for	NULL
cAMP	NULL
regulation	NULL
of	NULL
the	NULL
proenkephalin	NULL
gene	NULL
(	NULL
14	NULL
)	NULL
.	NULL

CRE-2	NULL
(	NULL
TGCGTCA	NULL
)	NULL
is	NULL
a	NULL
site	NULL
that	NULL
most	NULL
closely	NULL
resembles	NULL
the	NULL
phorbol	NULL
ester	NULL
response	NULL
element	NULL
(	NULL
tetradecanoylphorbol	NULL
acetate	NULL
response	NULL
element	NULL
,	NULL
TRE	NULL
)	NULL
(	NULL
TGACTCA	NULL
)	NULL
but	NULL
also	NULL
contains	NULL
the	NULL
core	NULL
CGTCA	NULL
element	NULL
found	NULL
in	NULL
most	NULL
CREs	NULL
(	NULL
14	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
affinity-purified	NULL
AP-1	NULL
proteins	NULL
bind	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
CRE-2	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

This	NULL
information	NULL
focused	NULL
our	NULL
attention	NULL
on	NULL
proteins	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
(	NULL
Fos	NULL
,	NULL
Jun	NULL
,	NULL
and	NULL
related	NULL
molecules	NULL
)	NULL
,	NULL
which	NULL
were	NULL
originally	NULL
identified	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
and	NULL
activate	NULL
transcription	NULL
via	NULL
the	NULL
TRE	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
JunD	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
,	NULL
transactivates	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
at	NULL
the	NULL
CRE-2	NULL
element	NULL
.	NULL

JunB	NULL
is	NULL
shown	NULL
to	NULL
antagonize	NULL
activation	NULL
mediated	NULL
by	NULL
JunD	NULL
.	NULL

DNA	NULL
binding	NULL
studies	NULL
indicate	NULL
that	NULL
JunB	NULL
alone	NULL
does	NULL
not	NULL
bind	NULL
CRE-2	NULL
but	NULL
can	NULL
bind	NULL
this	NULL
element	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
c-Fos	NULL
.	NULL

Together	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
AP-1	NULL
complexes	NULL
involving	NULL
JunD	NULL
and	NULL
JunB	NULL
may	NULL
act	NULL
to	NULL
induce	NULL
or	NULL
repress	NULL
proenkephalin	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
cAMP	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
our	NULL
data	NULL
suggest	NULL
that	NULL
cAMP	NULL
regulates	NULL
gene	NULL
expression	NULL
through	NULL
at	NULL
least	NULL
two	NULL
pathways	NULL
:	NULL
one	NULL
that	NULL
involves	NULL
previously	NULL
described	NULL
CREB/ATF	NULL
proteins	NULL
acting	NULL
at	NULL
classic	NULL
CRE	NULL
sequences	NULL
(	NULL
18-21	NULL
)	NULL
and	NULL
a	NULL
second	NULL
pathway	NULL
involving	NULL
AP-1	NULL
proteins	NULL
acting	NULL
at	NULL
both	NULL
CRE-	NULL
and	NULL
TRE-like	NULL
sequences	NULL
.	NULL

METHODS	NULL
AND	NULL
MATERIALS	NULL
Cell	NULL
Culture	NULL
.	NULL

C6	NULL
glioma	NULL
cells	NULL
and	NULL
C6-D2	NULL
(	NULL
16	NULL
)	NULL
,	NULL
a	NULL
line	NULL
stably	NULL
transfected	NULL
with	NULL
pENKAT-12	NULL
,	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
DMEM	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

F9	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
calf	NULL
serum	NULL
.	NULL

Northern	NULL
Blot	NULL
Analysis	NULL
.	NULL

For	NULL
the	NULL
analysis	NULL
of	NULL
RNA	NULL
in	NULL
C6-D2	NULL
cells	NULL
stimulated	NULL
with	NULL
forskolin	NULL
,	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
low-serum	NULL
medium	NULL
(	NULL
0.5	NULL
%	NULL
)	NULL
for	NULL
14-16	NULL
hr	NULL
,	NULL
treated	NULL
with	NULL
25	NULL
uM	NULL
forskolin	NULL
and	NULL
0.5	NULL
mM	NULL
3-isobutyl-1-methylxanthine	NULL
(	NULL
IBMX	NULL
)	NULL
,	NULL
and	NULL
harvested	NULL
at	NULL
various	NULL
times	NULL
after	NULL
treatment	NULL
from	NULL
15	NULL
min	NULL
to	NULL
14	NULL
hr	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
Abbreviations	NULL
:	NULL
PKA	NULL
,	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
;	NULL
TRE	NULL
,	NULL
phorbol	NULL
ester	NULL
response	NULL
element	NULL
;	NULL
CRE	NULL
,	NULL
cAMP	NULL
response	NULL
element	NULL
;	NULL
CREB	NULL
,	NULL
CRE-binding	NULL
protein	NULL
;	NULL
IBMX	NULL
,	NULL
3-isobutyl-l-methylxanthine	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
BGal	NULL
,	NULL
B-galactosidase	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Neurobiology	NULL
:	NULL
Kobierski	NULL
et	NULL
al	NULL
.	NULL

anisomycin	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
or	NULL
cycloheximide	NULL
(	NULL
100	NULL
LM	NULL
)	NULL
was	NULL
added	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
forskolin	NULL
stimulation	NULL
.	NULL

Total	NULL
cytoplasmic	NULL
RNA	NULL
was	NULL
isolated	NULL
as	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
junD	NULL
probe	NULL
(	NULL
bp	NULL
58-577	NULL
)	NULL
and	NULL
junB	NULL
probe	NULL
(	NULL
bp	NULL
33-427	NULL
)	NULL
each	NULL
included	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
and	NULL
coding	NULL
sequence	NULL
.	NULL

The	NULL
c-fos	NULL
probe	NULL
(	NULL
26	NULL
)	NULL
was	NULL
a	NULL
1.5-kilobase	NULL
(	NULL
kb	NULL
)	NULL
fragment	NULL
that	NULL
includes	NULL
the	NULL
entire	NULL
c-fos	NULL
coding	NULL
region	NULL
.	NULL

Plasmid	NULL
Constructions	NULL
.	NULL

To	NULL
construct	NULL
the	NULL
RSVJunD	NULL
expression	NULL
vector	NULL
,	NULL
a	NULL
1.7-kb	NULL
Sac	NULL
I-EcoRV	NULL
fragment	NULL
containing	NULL
the	NULL
entire	NULL
junD	NULL
coding	NULL
sequence	NULL
and	NULL
untranslated	NULL
flanking	NULL
sequences	NULL
was	NULL
isolated	NULL
from	NULL
a	NULL
junD	NULL
cDNA-containing	NULL
plasmid	NULL
(	NULL
24	NULL
)	NULL
and	NULL
cloned	NULL
into	NULL
RSV-SG	NULL
(	NULL
18	NULL
)	NULL
cut	NULL
with	NULL
Bgl	NULL
II	NULL
(	NULL
filled	NULL
in	NULL
)	NULL
and	NULL
Sac	NULL
I	NULL
.	NULL

The	NULL
RSV	NULL
JunB	NULL
vector	NULL
was	NULL
constructed	NULL
by	NULL
isolating	NULL
the	NULL
junB	NULL
cDNA	NULL
from	NULL
p465.20	NULL
(	NULL
25	NULL
)	NULL
after	NULL
a	NULL
complete	NULL
Xho	NULL
I	NULL
(	NULL
filled	NULL
in	NULL
)	NULL
digestion	NULL
and	NULL
a	NULL
partial	NULL
Sac	NULL
I	NULL
digestion	NULL
.	NULL

The	NULL
1.5-kb	NULL
fragment	NULL
containing	NULL
the	NULL
entire	NULL
junB	NULL
coding	NULL
sequence	NULL
and	NULL
5	NULL
'	NULL
untranslated	NULL
sequences	NULL
was	NULL
then	NULL
cloned	NULL
into	NULL
the	NULL
RSV-SG	NULL
backbone	NULL
.	NULL

The	NULL
proenkephalin	NULL
multicopy	NULL
element	NULL
plasmids	NULL
(	NULL
pENKCRE-2	NULL
,	NULL
pENKCRE-1	NULL
,	NULL
pENKAP-4	NULL
)	NULL
were	NULL
constructed	NULL
using	NULL
the	NULL
oligonucleotides	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

pENKCRE-2	NULL
contains	NULL
five	NULL
tandem	NULL
copies	NULL
of	NULL
CRE-2	NULL
(	NULL
16	NULL
)	NULL
.	NULL

pENKCRE-1	NULL
and	NULL
pENKAP-4	NULL
contain	NULL
five	NULL
to	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
CRE-1	NULL
and	NULL
AP-4	NULL
sites	NULL
,	NULL
respectively	NULL
.	NULL

Transient	NULL
Transfections	NULL
and	NULL
Chloramphenicol	NULL
Acetyitrans-ferase	NULL
(	NULL
CAT	NULL
)	NULL
Assays	NULL
.	NULL

F9	NULL
cells	NULL
and	NULL
C6	NULL
glioma	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
10-cm	NULL
plate	NULL
)	NULL
were	NULL
transiently	NULL
cotransfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
with	NULL
a	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
and	NULL
the	NULL
following	NULL
plasmids	NULL
in	NULL
various	NULL
combinations	NULL
as	NULL
indicated	NULL
.	NULL

in	NULL
the	NULL
text	NULL
and	NULL
figure	NULL
legends	NULL
:	NULL
pRSVJunD	NULL
;	NULL
pRSVJunB	NULL
;	NULL
pMTCaneo	NULL
(	NULL
27	NULL
)	NULL
;	NULL
pRSV	NULL
B-galactosidase	NULL
(	NULL
BGal	NULL
;	NULL
ref	NULL
.	NULL

28	NULL
)	NULL
.	NULL

After	NULL
3.5	NULL
hr	NULL
the	NULL
cells	NULL
were	NULL
glycerol-shocked	NULL
for	NULL
3	NULL
min	NULL
and	NULL
then	NULL
harvested	NULL
24	NULL
hr	NULL
later	NULL
for	NULL
protein	NULL
extracts	NULL
.	NULL

CAT	NULL
and	NULL
BGal	NULL
activities	NULL
were	NULL
measured	NULL
as	NULL
described	NULL
(	NULL
13	NULL
)	NULL
with	NULL
the	NULL
exception	NULL
that	NULL
lysates	NULL
were	NULL
heat-inactivated	NULL
at	NULL
65°C	NULL
for	NULL
10	NULL
min	NULL
(	NULL
only	NULL
for	NULL
CAT	NULL
assays	NULL
)	NULL
.	NULL

In	NULL
Vitro	NULL
Synthesis	NULL
of	NULL
Proteins	NULL
.	NULL

Fifty	NULL
to	NULL
100	NULL
ng	NULL
of	NULL
RNA	NULL
was	NULL
transcribed	NULL
in	NULL
vitro	NULL
from	NULL
pGEM-2	NULL
plasmids	NULL
containing	NULL
the	NULL
complete	NULL
coding	NULL
sequences	NULL
for	NULL
either	NULL
junB	NULL
(	NULL
25	NULL
)	NULL
,	NULL
junD	NULL
(	NULL
29	NULL
)	NULL
,	NULL
or	NULL
c-fos	NULL
(	NULL
gift	NULL
of	NULL
J.	NULL
G.	NULL
Belasco	NULL
and	NULL
M.	NULL
E.	NULL
Greenberg	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
)	NULL
and	NULL
then	NULL
was	NULL
translated	NULL
in	NULL
rabbit	NULL
reticulocyte	NULL
lysates	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

[	NULL
*S	NULL
)	NULL
Methionine-labeled	NULL
translation	NULL
products	NULL
were	NULL
analyzed	NULL
by	NULL
SDS/PAGE	NULL
.	NULL

Prestained	NULL
protein	NULL
standards	NULL
(	NULL
M	NULL
,	NULL
15,000-110,000	NULL
;	NULL
Bio-Rad	NULL
)	NULL
were	NULL
used	NULL
to	NULL
determine	NULL
molecular	NULL
weight	NULL
.	NULL

Gel	NULL
Retardation	NULL
Assay	NULL
.	NULL

A	NULL
double-stranded	NULL
oligonucleotide	NULL
spanning	NULL
-110	NULL
to	NULL
-80	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
was	NULL
labeled	NULL
using	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
and	NULL
(	NULL
3000	NULL
CRE	NULL
CRE-90	NULL
AT	NULL
I	NULL
LML	NULL
M	NULL
T	NULL
’	NULL
EGCLTA1	NULL
GGGco	NULL
TGCGTC	NULL
GCTGCAG	NULL
ufa	NULL
,	NULL
CAGCCGCGCCCCC	NULL
ACCGCAT	NULL
CCCGGIACGCAGT	NULL
]	NULL
CGACGTCGGGCC	NULL
GATCGCG	NULL
CC	NULL
CGACCGCATCCCCTAG	NULL
3	NULL
CCGACGCAGTCCCCTAG	NULL
GATCGTCAGCTG	NULL
CAGTCGAC	NULL
ATCGGGCTGGCGTaAGGGCCTGcGTcAGcTC	NULL
C	NULL
CCCGACCGCATCCCGGACGCAGTCGACGTCTAG	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Human	NULL
proenkephalin	NULL
second-messenger-inducible	NULL
enhancer	NULL
.	NULL

Sequence	NULL
spanning	NULL
bp	NULL
-117	NULL
to	NULL
-74	NULL
of	NULL
the	NULL
proenkephalin	NULL
gene	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
CRE-1	NULL
and	NULL
CRE-2	NULL
elements	NULL
are	NULL
boxed	NULL
and	NULL
the	NULL
AP-4	NULL
and	NULL
AP-2	NULL
elements	NULL
are	NULL
highlighted	NULL
by	NULL
stippling	NULL
.	NULL

Oligonucleotides	NULL
used	NULL
in	NULL
gel	NULL
shift	NULL
assays	NULL
and	NULL
to	NULL
construct	NULL
multicopy	NULL
element	NULL
plasmids	NULL
are	NULL
shown	NULL
and	NULL
identified	NULL
by	NULL
the	NULL
enhancer	NULL
element	NULL
that	NULL
they	NULL
contain	NULL
.	NULL

Bases	NULL
within	NULL
CRE-2	NULL
that	NULL
are	NULL
mutated	NULL
in	NULL
oligonucleotides	NULL
used	NULL
in	NULL
gel	NULL
shift	NULL
and	NULL
cotransfection	NULL
assays	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
-	NULL
10223	NULL
Ci/mmol	NULL
;	NULL
1	NULL
Ci	NULL
=	NULL
37	NULL
GBq	NULL
)	NULL
.	NULL

Binding	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
15	NULL
ul	NULL
of	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
8.0/15	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol/0.2	NULL
mM	NULL
EDTA/50	NULL
mM	NULL
KCI/2	NULL
mM	NULL
MgCl	NULL
;	NULL
/2	NULL
mM	NULL
dithiothreitol	NULL
containing	NULL
1	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

Translation	NULL
products	NULL
(	NULL
1	NULL
ul	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
above	NULL
reaction	NULL
buffer	NULL
with	NULL
1-2	NULL
ng	NULL
of	NULL
labeled	NULL
probe	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Reaction	NULL
mixtures	NULL
were	NULL
then	NULL
analyzed	NULL
by	NULL
PAGE	NULL
as	NULL
described	NULL
(	NULL
29	NULL
)	NULL
.	NULL

RESULTS	NULL
Expression	NULL
and	NULL
Regulation	NULL
of	NULL
Proenkephalin	NULL
,	NULL
JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
c-Fos	NULL
in	NULL
C6	NULL
Glioma	NULL
Cells	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
time	NULL
course	NULL
and	NULL
protein	NULL
synthesis	NULL
dependence	NULL
of	NULL
proenkephalin	NULL
activation	NULL
by	NULL
cAMP	NULL
we	NULL
analyzed	NULL
the	NULL
kinetics	NULL
of	NULL
a	NULL
CAT	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
encoded	NULL
by	NULL
a	NULL
stably	NULL
expressed	NULL
proenkephalin-CAT	NULL
fusion	NULL
gene	NULL
in	NULL
C6	NULL
glioma	NULL
cells	NULL
stimulated	NULL
by	NULL
forskolin	NULL
,	NULL
an	NULL
activator	NULL
of	NULL
adenylate	NULL
cyclase	NULL
,	NULL
and	NULL
IBMX	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
phosphodiesterase	NULL
.	NULL

Induction	NULL
of	NULL
cytoplasmic	NULL
RNA	NULL
was	NULL
observed	NULL
within	NULL
15	NULL
min	NULL
of	NULL
forskolin	NULL
addition	NULL
,	NULL
peaked	NULL
between	NULL
1	NULL
and	NULL
2	NULL
hr	NULL
,	NULL
and	NULL
was	NULL
significantly	NULL
reduced	NULL
by	NULL
8	NULL
hr	NULL
.	NULL

Induction	NULL
was	NULL
not	NULL
blocked	NULL
by	NULL
pretreatment	NULL
with	NULL
cycloheximide	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
anisomycin	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
;	NULL
however	NULL
,	NULL
the	NULL
decline	NULL
in	NULL
message	NULL
levels	NULL
observed	NULL
between	NULL
3	NULL
and	NULL
8	NULL
hr	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
these	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Protein	NULL
synthesis	NULL
inhibitors	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
forskolin	NULL
and	NULL
IBMX	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
proenkephalin	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Endogenous	NULL
proenkephalin	NULL
transcripts	NULL
show	NULL
a	NULL
similar	NULL
pattern	NULL
of	NULL
expression	NULL
although	NULL
the	NULL
time	NULL
course	NULL
is	NULL
less	NULL
informative	NULL
due	NULL
to	NULL
the	NULL
high	NULL
level	NULL
of	NULL
basal	NULL
proenkephalin	NULL
mRNA	NULL
and	NULL
its	NULL
long	NULL
half-life	NULL
compared	NULL
with	NULL
CAT	NULL
mRNA	NULL
(	NULL
0.5	NULL
day	NULL
versus	NULL
several	NULL
hours	NULL
)	NULL
(	NULL
11	NULL
)	NULL
.	NULL

As	NULL
a	NULL
first	NULL
step	NULL
in	NULL
determining	NULL
what	NULL
role	NULL
different	NULL
AP-1	NULL
components	NULL
may	NULL
play	NULL
in	NULL
the	NULL
forskolin-induced	NULL
stimulation	NULL
of	NULL
proenkephalin	NULL
transcription	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
expression	NULL
of	NULL
mRNAs	NULL
encoding	NULL
three	NULL
AP-1	NULL
factors-JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
c-Fos-before	NULL
and	NULL
after	NULL
treatment	NULL
of	NULL
C6	NULL
glioma	NULL
cells	NULL
with	NULL
forskolin	NULL
and	NULL
IBMX	NULL
.	NULL

Significant	NULL
levels	NULL
of	NULL
junD	NULL
RNA	NULL
were	NULL
constitutively	NULL
expressed	NULL
in	NULL
the	NULL
C6	NULL
glioma	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

One	NULL
hour	NULL
after	NULL
treatment	NULL
with	NULL
forskolin	NULL
and	NULL
IBMX	NULL
,	NULL
junD	NULL
RNA	NULL
levels	NULL
decreased	NULL
severalfold	NULL
and	NULL
remained	NULL
lowered	NULL
up	NULL
to	NULL
14	NULL
hr	NULL
later	NULL
.	NULL

RNAs	NULL
encoding	NULL
JunB	NULL
and	NULL
c-Fos	NULL
were	NULL
not	NULL
detectable	NULL
c-Fos	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

A	NULL
C6	NULL
glioma	NULL
cell	NULL
line	NULL
(	NULL
C6-D2	NULL
)	NULL
stably	NULL
transfected	NULL
with	NULL
pENKAT-12	NULL
was	NULL
treated	NULL
for	NULL
various	NULL
intervals	NULL
(	NULL
as	NULL
indicated	NULL
in	NULL
hours	NULL
above	NULL
each	NULL
lane	NULL
)	NULL
with	NULL
25	NULL
uM	NULL
forskolin	NULL
and	NULL
500	NULL
uM	NULL
IBMX	NULL
.	NULL

Total	NULL
cytoplasmic	NULL
RNA	NULL
was	NULL
isolated	NULL
and	NULL
20-ug	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Activity	NULL
of	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
cDNA	NULL
probe	NULL
specific	NULL
for	NULL
CAT	NULL
(	NULL
derived	NULL
from	NULL
pENKAT-12	NULL
)	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
C6-D2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
uM	NULL
anisomycin	NULL
(	NULL
ANISO	NULL
.	NULL
)	NULL

30	NULL
min	NULL
prior	NULL
to	NULL
forskolin	NULL
stimulation	NULL
and	NULL
the	NULL
resultant	NULL
RNA	NULL
was	NULL
hybridized	NULL
with	NULL
the	NULL
CAT	NULL
cDNA	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RNA	NULL
isolated	NULL
from	NULL
C6-D2	NULL
cells	NULL
treated	NULL
with	NULL
forskolin	NULL
and	NULL
IBMX	NULL
also	NULL
was	NULL
hybridized	NULL
with	NULL
cDNA	NULL
probes	NULL
specific	NULL
for	NULL
JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
c-Fos	NULL
.	NULL

10224	NULL
-	NULL
Neurobiology	NULL
:	NULL
Kobierski	NULL
et	NULL
al	NULL
.	NULL

in	NULL
untreated	NULL
control	NULL
C6	NULL
glioma	NULL
cells	NULL
but	NULL
were	NULL
rapidly	NULL
and	NULL
transiently	NULL
induced	NULL
by	NULL
forskolin	NULL
and	NULL
IBMX	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Transactivation	NULL
by	NULL
JunD	NULL
Is	NULL
Dependent	NULL
Upon	NULL
PKA	NULL
and	NULL
CRE-2	NULL
.	NULL

To	NULL
test	NULL
the	NULL
functional	NULL
activity	NULL
of	NULL
different	NULL
AP-1	NULL
components	NULL
at	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
,	NULL
we	NULL
introduced	NULL
full-length	NULL
cDNAs	NULL
encoding	NULL
JunD	NULL
and	NULL
JunB	NULL
into	NULL
expression	NULL
vectors	NULL
utilizing	NULL
a	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
(	NULL
RSV	NULL
)	NULL
promoter/	NULL
enhancer	NULL
and	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
polyadenylylation	NULL
site	NULL
.	NULL

These	NULL
expression	NULL
vectors	NULL
(	NULL
pRSVJunD	NULL
and	NULL
pRSV	NULL
JunB	NULL
)	NULL
were	NULL
then	NULL
used	NULL
to	NULL
drive	NULL
constitutive	NULL
expression	NULL
in	NULL
a	NULL
number	NULL
of	NULL
different	NULL
cell	NULL
lines	NULL
after	NULL
transfection	NULL
and	NULL
transient	NULL
expression	NULL
.	NULL

Expression	NULL
was	NULL
first	NULL
investigated	NULL
in	NULL
undifferentiated	NULL
F9	NULL
cells	NULL
,	NULL
as	NULL
these	NULL
cells	NULL
express	NULL
low	NULL
or	NULL
undetectable	NULL
levels	NULL
of	NULL
AP-1	NULL
DNA-binding	NULL
activity	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
proenkephalin-CAT	NULL
fusion	NULL
gene	NULL
,	NULL
pENKAT-12	NULL
(	NULL
13	NULL
)	NULL
,	NULL
was	NULL
expressed	NULL
in	NULL
these	NULL
cells	NULL
at	NULL
very	NULL
low	NULL
levels	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
bar	NULL
a	NULL
)	NULL
.	NULL

Cotransfection	NULL
with	NULL
pRSVJunD	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
CAT	NULL
expression	NULL
driven	NULL
by	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
,	NULL
whereas	NULL
cotransfection	NULL
with	NULL
a	NULL
plasmid	NULL
expressing	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PKA	NULL
,	NULL
pMTCaneo	NULL
(	NULL
27	NULL
)	NULL
,	NULL
produced	NULL
a	NULL
reproducible	NULL
2-	NULL
to	NULL
S-fold	NULL
increase	NULL
in	NULL
CAT	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
bars	NULL
b	NULL
and	NULL
c	NULL
)	NULL
.	NULL

Cotransfection	NULL
of	NULL
pENKAT-12	NULL
together	NULL
with	NULL
JunD-	NULL
and	NULL
PKA-expressing	NULL
plasmids	NULL
produced	NULL
a	NULL
10-	NULL
to	NULL
30-fold	NULL
increase	NULL
in	NULL
CAT	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
bar	NULL
d	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
transactivation	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
by	NULL
JunD	NULL
is	NULL
dependent	NULL
upon	NULL
expression	NULL
of	NULL
an	NULL
active	NULL
PKA	NULL
catalytic	NULL
subunit	NULL
.	NULL

Similar	NULL
observations	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
have	NULL
been	NULL
made	NULL
in	NULL
C6	NULL
glioma	NULL
cells	NULL
which	NULL
express	NULL
the	NULL
proenkephalin	NULL
gene	NULL
and	NULL
regulate	NULL
it	NULL
in	NULL
a	NULL
forskolin	NULL
dependent	NULL
fashion	NULL
.	NULL

However	NULL
,	NULL
because	NULL
transfections	NULL
with	NULL
PKA	NULL
alone	NULL
produce	NULL
such	NULL
large	NULL
effects	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
it	NULL
was	NULL
necessary	NULL
to	NULL
reduce	NULL
the	NULL
amount	NULL
of	NULL
pMTCaneo	NULL
in	NULL
order	NULL
to	NULL
observe	NULL
the	NULL
effect	NULL
of	NULL
JunD	NULL
.	NULL

To	NULL
map	NULL
the	NULL
elements	NULL
essential	NULL
for	NULL
transactivation	NULL
by	NULL
JunD	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
pRSVJunD	NULL
and	NULL
pMTCaneo	NULL
on	NULL
plasmids	NULL
that	NULL
contained	NULL
multiple	NULL
copies	NULL
of	NULL
each	NULL
element	NULL
(	NULL
CRE-2	NULL
,	NULL
CRE-1	NULL
,	NULL
AP-4	NULL
;	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
cloned	NULL
into	NULL
a	NULL
plasmid	NULL
,	NULL
pENKAT-A80	NULL
,	NULL
that	NULL
has	NULL
all	NULL
enhancer	NULL
elements	NULL
removed	NULL
and	NULL
no	NULL
longer	NULL
responds	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
second-messenger	NULL
pathways	NULL
.	NULL

Multiple	NULL
copies	NULL
of	NULL
the	NULL
CRE-2	NULL
element	NULL
but	NULL
not	NULL
the	NULL
CRE-1	NULL
or	NULL
AP-4	NULL
element	NULL
reconstitute	NULL
wild-type	NULL
enhancer	NULL
transactivation	NULL
by	NULL
JunD	NULL
and	NULL
PKA	NULL
in	NULL
transiently	NULL
transfected	NULL
F9	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
point	NULL
mutations	NULL
within	NULL
CRE-2	NULL
that	NULL
block	NULL
second-messenger	NULL
regulation	NULL
in	NULL
vivo	NULL
(	NULL
14	NULL
)	NULL
also	NULL
block	NULL
transactivation	NULL
by	NULL
JunD	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

All	NULL
CAT	NULL
activities	NULL
shown	NULL
are	NULL
normalized	NULL
to	NULL
BGal	NULL
activities	NULL
measured	NULL
from	NULL
the	NULL
same	NULL
extracts	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

A	NULL
B	NULL
t	NULL
?	NULL

sd	NULL
2	NULL
50	NULL
$	NULL
50	NULL
%	NULL
l	NULL
3	NULL
4	NULL
0	NULL
&	NULL
~	NULL
30	NULL
V	NULL
30	NULL
&	NULL
n	NULL
E	NULL
é	NULL
5	NULL
20	NULL
<	NULL
10	NULL
G	NULL
10	NULL
E	NULL
<	NULL
<	NULL
0	NULL
»	NULL
0	NULL
U	NULL
a	NULL
b	NULL
co	NULL
d	NULL
5	NULL
a	NULL
boc	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
JunB	NULL
Inhibits	NULL
PK	NULL
A-Dependent	NULL
Transactivation	NULL
by	NULL
JunD	NULL
.	NULL

To	NULL
gain	NULL
insight	NULL
into	NULL
the	NULL
functional	NULL
effects	NULL
of	NULL
JunB	NULL
we	NULL
carried	NULL
out	NULL
cotransfection	NULL
experiments	NULL
with	NULL
pRSVJunB	NULL
.	NULL

In	NULL
F9	NULL
cells	NULL
,	NULL
JunB	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
PKA	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
transcription	NULL
from	NULL
the	NULL
proenkephalin-CAT	NULL
fusion	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
small	NULL
,	NULL
3-fold	NULL
effect	NULL
seen	NULL
together	NULL
with	NULL
PKA	NULL
was	NULL
indistinguishable	NULL
from	NULL
the	NULL
effect	NULL
seen	NULL
with	NULL
PKA	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
when	NULL
a	NULL
JunB	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
JunD-	NULL
and	NULL
PKA-expressing	NULL
plasmids	NULL
,	NULL
a	NULL
dose-dependent	NULL
reduction	NULL
in	NULL
JunD	NULL
transactivation	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

When	NULL
cotransfected	NULL
with	NULL
JunD	NULL
at	NULL
a	NULL
4-fold	NULL
molar	NULL
excess	NULL
,	NULL
JunB	NULL
dramatically	NULL
inhibited	NULL
the	NULL
transactivation	NULL
observed	NULL
with	NULL
JunD	NULL
and	NULL
PKA	NULL
.	NULL

Neither	NULL
JunB	NULL
nor	NULL
JunD	NULL
had	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
pRSV	NULL
BGal	NULL
plasmid	NULL
,	NULL
which	NULL
was	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

This	NULL
observation	NULL
makes	NULL
it	NULL
unlikely	NULL
that	NULL
inhibition	NULL
by	NULL
JunB	NULL
is	NULL
due	NULL
to	NULL
the	NULL
titration	NULL
of	NULL
limiting	NULL
factors	NULL
required	NULL
by	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter	NULL
.	NULL

Characterization	NULL
of	NULL
JunD	NULL
and	NULL
JunB	NULL
Binding	NULL
at	NULL
the	NULL
Proenkephalin	NULL
Enhancer	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
binding	NULL
of	NULL
JunD	NULL
and	NULL
JunB	NULL
to	NULL
CRE-2	NULL
,	NULL
we	NULL
transcribed	NULL
RNA	NULL
encoding	NULL
JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
c-Fos	NULL
and	NULL
then	NULL
translated	NULL
these	NULL
individually	NULL
and	NULL
in	NULL
combi-nations	NULL
,	NULL
as	NULL
described	NULL
below	NULL
,	NULL
in	NULL
rabbit	NULL
reticulocyte	NULL
lysates	NULL
.	NULL

Fig	NULL
.	NULL

5A	NULL
shows	NULL
in	NULL
vitro	NULL
translated	NULL
,	NULL
JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
c-Fos	NULL
proteins	NULL
.	NULL

Lysates	NULL
used	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
assays	NULL
described	NULL
below	NULL
were	NULL
translated	NULL
in	NULL
parallel	NULL
under	NULL
identical	NULL
conditions	NULL
except	NULL
for	NULL
the	NULL
replacement	NULL
of	NULL
[	NULL
>	NULL
S	NULL
)	NULL
Jmethionine	NULL
with	NULL
nonradioactive	NULL
methionine	NULL
.	NULL

Control	NULL
lysates	NULL
showed	NULL
no	NULL
specific	NULL
binding	NULL
to	NULL
a	NULL
30-bp	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
from	NULL
-110	NULL
to	NULL
-80	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
lysates	NULL
programmed	NULL
with	NULL
JunD	NULL
RNA	NULL
produced	NULL
a	NULL
shifted	NULL
band	NULL
(	NULL
arrowhead	NULL
,	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
whose	NULL
formation	NULL
was	NULL
specifically	NULL
inhibited	NULL
by	NULL
unlabeled	NULL
proenkephalin	NULL
enhancer	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
but	NULL
not	NULL
by	NULL
AP-2	NULL
or	NULL
AP-4	NULL
oligonucleotides	NULL
and	NULL
only	NULL
very	NULL
weakly	NULL
by	NULL
a	NULL
CRE-1	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
5-7	NULL
)	NULL
.	NULL

Both	NULL
TRE	NULL
and	NULL
CRE	NULL
oligonucleotides	NULL
competed	NULL
effectively	NULL
for	NULL
JunD	NULL
DNA	NULL
binding	NULL
(	NULL
lanes	NULL
8-11	NULL
)	NULL
.	NULL

We	NULL
next	NULL
attempted	NULL
to	NULL
correlate	NULL
binding	NULL
of	NULL
JunD	NULL
with	NULL
the	NULL
in	NULL
vivo	NULL
functional	NULL
activity	NULL
of	NULL
a	NULL
series	NULL
of	NULL
single	NULL
base	NULL
substitution	NULL
mutations	NULL
spanning	NULL
CRE-2	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
a	NULL
wild-type	NULL
CRE-2	NULL
oligonucleotide	NULL
(	NULL
-93	NULL
to	NULL
-85	NULL
bp	NULL
,	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
was	NULL
used	NULL
as	NULL
nonradioactive	NULL
competitor	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lanes	NULL
12	NULL
and	NULL
13	NULL
)	NULL
and	NULL
this	NULL
competition	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
CRE-2	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
indicated	NULL
single	NULL
base	NULL
substitution	NULL
mutation	NULL
(	NULL
lanes	NULL
14-16	NULL
)	NULL
.	NULL

Mutations	NULL
within	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
CRE-2	NULL
,	NULL
which	NULL
have	NULL
the	NULL
most	NULL
profound	NULL
effect	NULL
on	NULL
second-messenger	NULL
regulation	NULL
of	NULL
proenkephalin	NULL
transcription	NULL
(	NULL
14	NULL
)	NULL
,	NULL
C	NULL
3	NULL
-A	NULL
60	NULL
x	NULL
ésolﬁ	NULL
g	NULL
m	NULL
CONTROL	NULL
é	NULL
i	NULL
Jun-D/PKA	NULL
EZO	NULL
Q	NULL
10	NULL
<	NULL
0	NULL
°o	NULL
py	NULL
5g	NULL
gob	NULL
c	NULL
®	NULL
®	NULL
T	NULL
U	NULL
-	NULL
O	NULL
i	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

JunD	NULL
transactivation	NULL
of	NULL
proenkephalin	NULL
is	NULL
PKA-dependent	NULL
and	NULL
maps	NULL
to	NULL
the	NULL
CRE-2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
F9	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
pENKAT-12	NULL
and	NULL
pRSV	NULL
BGal	NULL
in	NULL
various	NULL
combinations	NULL
with	NULL
pRSVJunD	NULL
and	NULL
pMTCaneo	NULL
as	NULL
follows	NULL
:	NULL
bar	NULL
a	NULL
,	NULL
pENKAT-12	NULL
alone	NULL
;	NULL
bar	NULL
b	NULL
,	NULL
pENKAT-12	NULL
plus	NULL
5	NULL
ug	NULL
of	NULL
pRSVJunD	NULL
;	NULL
bar	NULL
c	NULL
,	NULL
pENKAT-12	NULL
plus	NULL
10	NULL
ug	NULL
of	NULL
pMTCaneo	NULL
;	NULL
bar	NULL
d	NULL
,	NULL
pENKAT-12	NULL
plus	NULL
5	NULL
ug	NULL
of	NULL
pRSVJunD	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
pMTCaneo	NULL
.	NULL

The	NULL
total	NULL
amount	NULL
of	NULL
DNA	NULL
was	NULL
maintained	NULL
at	NULL
40	NULL
ug	NULL
with	NULL
pGEM-3	NULL
.	NULL

(	NULL
B	NULL
)	NULL
C6	NULL
cells	NULL
were	NULL
cotransfected	NULL
as	NULL
described	NULL
above	NULL
with	NULL
two	NULL
exceptions	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
pMTCaneo	NULL
was	NULL
reduced	NULL
to	NULL
2	NULL
ug	NULL
and	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
DNA	NULL
was	NULL
maintained	NULL
at	NULL
25	NULL
ug	NULL
with	NULL
pGEM-3	NULL
.	NULL

(	NULL
C	NULL
)	NULL
F9	NULL
cells	NULL
were	NULL
transfected	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
following	NULL
:	NULL
pENKAT-12	NULL
;	NULL
pENKAT	NULL
-	NULL
A80	NULL
;	NULL
pENKCRE	NULL
-	NULL
2	NULL
;	NULL
pENKCRE	NULL
-	NULL
1	NULL
;	NULL
pENKAP	NULL
-	NULL
4	NULL
;	NULL
or	NULL
derivatives	NULL
of	NULL
pENKAT-12	NULL
in	NULL
which	NULL
single	NULL
bases	NULL
of	NULL
CRE-2	NULL
were	NULL
mutated	NULL
,	NULL
-86	NULL
(	NULL
A	NULL
to	NULL
T	NULL
)	NULL
,	NULL
-87	NULL
(	NULL
C	NULL
to	NULL
T	NULL
)	NULL
,	NULL
or	NULL
-88	NULL
(	NULL
T	NULL
to	NULL
A	NULL
)	NULL
.	NULL

CAT-expressing	NULL
plasmids	NULL
also	NULL
were	NULL
cotransfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
pRSVJunD	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
pMTCaneo	NULL
(	NULL
striped	NULL
bars	NULL
)	NULL
.	NULL

All	NULL
CAT	NULL
activities	NULL
were	NULL
normalized	NULL
for	NULL
expression	NULL
of	NULL
pRSVBGal	NULL
.	NULL

These	NULL
results	NULL
were	NULL
repeated	NULL
at	NULL
least	NULL
three	NULL
times	NULL
.	NULL

Neurobiology	NULL
:	NULL
Kobierski	NULL
et	NULL
al	NULL
.	NULL

40	NULL
30	NULL
20	NULL
10	NULL
CAT	NULL
ACTIVITY	NULL
,	NULL
CPM	NULL
X	NULL
10-3	NULL
0	NULL
pENKAT12	NULL
t	NULL
*+	NULL
_	NULL
+	NULL
pRSVJun-D	NULL
-	NULL
-	NULL
pMTCaneo	NULL
_	NULL
-	NULL
=	NULL
+	NULL
pRSVJun-B	NULL
-	NULL
5	NULL
5	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
10	NULL
20	NULL
bot	NULL
40+	NULL
w	NULL
4	NULL
4	NULL
+	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

JunB	NULL
represses	NULL
transactivation	NULL
of	NULL
proenkephalin	NULL
by	NULL
JunD	NULL
.	NULL

F9	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
pENKAT-12	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
pRSVJunD	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
pMTCaneo	NULL
,	NULL
and	NULL
5	NULL
,	NULL
10	NULL
,	NULL
or	NULL
20	NULL
ug	NULL
of	NULL
pRSVJunB	NULL
as	NULL
indicated	NULL
.	NULL

Five	NULL
nanograms	NULL
of	NULL
pRSV	NULL
BGal	NULL
also	NULL
was	NULL
included	NULL
in	NULL
each	NULL
transfection	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
normalization	NULL
of	NULL
CAT	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
were	NULL
repeated	NULL
at	NULL
least	NULL
three	NULL
times	NULL
.	NULL

produced	NULL
the	NULL
most	NULL
severe	NULL
effect	NULL
on	NULL
JunD	NULL
binding	NULL
,	NULL
leading	NULL
to	NULL
a	NULL
lack	NULL
of	NULL
competition	NULL
.	NULL

Although	NULL
the	NULL
CRE-2	NULL
oligonucleotide	NULL
competed	NULL
for	NULL
JunD	NULL
binding	NULL
it	NULL
did	NULL
not	NULL
compete	NULL
as	NULL
well	NULL
as	NULL
oligonucleotides	NULL
that	NULL
included	NULL
both	NULL
CRE-1	NULL
and	NULL
CRE-2	NULL
and	NULL
flanking	NULL
sequences	NULL
(	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
with	NULL
12	NULL
and	NULL
13	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
binding	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
JunB	NULL
to	NULL
the	NULL
enhancer	NULL
was	NULL
not	NULL
observed	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Because	NULL
JunB	NULL
is	NULL
known	NULL
to	NULL
dimerize	NULL
with	NULL
JunD	NULL
(	NULL
29	NULL
)	NULL
and	NULL
c-Fos	NULL
(	NULL
29	NULL
,	NULL
31	NULL
)	NULL
,	NULL
we	NULL
also	NULL
analyzed	NULL
the	NULL
interaction	NULL
of	NULL
these	NULL
complexes	NULL
with	NULL
CRE-2	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
lane	NULL
3	NULL
,	NULL
lysates	NULL
programmed	NULL
with	NULL
equal	NULL
amounts	NULL
of	NULL
junB	NULL
and	NULL
junD	NULL
RNAs	NULL
bound	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
probe	NULL
with	NULL
an	NULL
affinity	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
junD-programmed	NULL
lysates	NULL
(	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
reports	NULL
using	NULL
AP-1	NULL
oligonucleotides	NULL
(	NULL
12	NULL
,	NULL
29	NULL
,	NULL
31	NULL
)	NULL
,	NULL
binding	NULL
to	NULL
CRE-2	NULL
was	NULL
observed	NULL
when	NULL
c-Fos	NULL
and	NULL
JunB	NULL
were	NULL
cotranslated	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
whereas	NULL
JunB	NULL
or	NULL
c-Fos	NULL
alone	NULL
did	NULL
not	NULL
bind	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Also	NULL
note	NULL
that	NULL
c-Fos	NULL
stimulated	NULL
the	NULL
binding	NULL
of	NULL
JunD	NULL
to	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Classic	NULL
CRE	NULL
and	NULL
TRE	NULL
also	NULL
Mediate	NULL
PKA-Dependent	NULL
Transcription	NULL
via	NULL
JunD	NULL
.	NULL

Because	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
contains	NULL
a	NULL
hybrid	NULL
TRE/CRE-like	NULL
element	NULL
,	NULL
CRE-2	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
JunD	NULL
to	NULL
transactivate	NULL
``	NULL
'classic	NULL
``	NULL
TRE	NULL
and	NULL
CRE	NULL
elements	NULL
in	NULL
a	NULL
PK	NULL
A-dependent	NULL
fashion	NULL
by	NULL
transiently	NULL
trans-fecting	NULL
F9	NULL
cells	NULL
with	NULL
plasmids	NULL
containing	NULL
the	NULL
somatostatin	NULL
CRE	NULL
,	NULL
pA	NULL
(	NULL
-71	NULL
)	NULL
CAT	NULL
(	NULL
32	NULL
)	NULL
,	NULL
or	NULL
the	NULL
collagenase	NULL
TRE	NULL
,	NULL
p-73Col-TRE	NULL
(	NULL
30	NULL
)	NULL
,	NULL
together	NULL
with	NULL
pRSVJunD	NULL
and	NULL
pMTCaneo	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
JunD	NULL
transactivated	NULL
the	NULL
somatostatin	NULL
CRE	NULL
=10-fold	NULL
and	NULL
the	NULL
collagenase	NULL
TRE	NULL
=~4-fold	NULL
.	NULL

These	NULL
results	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
-	NULL
10225	NULL
indicate	NULL
that	NULL
JunD	NULL
can	NULL
act	NULL
at	NULL
both	NULL
CREs	NULL
and	NULL
TREs	NULL
to	NULL
stimulate	NULL
transcription	NULL
in	NULL
a	NULL
PKA-dependent	NULL
fashion	NULL
.	NULL

DISCUSSION	NULL
Analysis	NULL
of	NULL
the	NULL
time	NULL
course	NULL
of	NULL
proenkephalin-CAT	NULL
RNA	NULL
expression	NULL
in	NULL
C6	NULL
glioma	NULL
cells	NULL
after	NULL
treatment	NULL
with	NULL
forskolin	NULL
or	NULL
with	NULL
forskolin	NULL
and	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
suggests	NULL
that	NULL
the	NULL
rapid	NULL
stimulation	NULL
of	NULL
the	NULL
proenkephalin-CAT	NULL
RNA	NULL
by	NULL
forskolin	NULL
is	NULL
independent	NULL
of	NULL
new	NULL
protein	NULL
synthesis	NULL
and	NULL
hence	NULL
mediated	NULL
by	NULL
preexisting	NULL
proteins	NULL
.	NULL

Several	NULL
properties	NULL
of	NULL
JunD	NULL
suggest	NULL
that	NULL
this	NULL
molecule	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
rapid	NULL
increase	NULL
in	NULL
RNA	NULL
levels	NULL
observed	NULL
after	NULL
stimulation	NULL
by	NULL
cAMP	NULL
and	NULL
possibly	NULL
other	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
.	NULL

First	NULL
,	NULL
unlike	NULL
all	NULL
other	NULL
known	NULL
members	NULL
of	NULL
the	NULL
Fos/Jun	NULL
family	NULL
,	NULL
the	NULL
level	NULL
of	NULL
junD	NULL
RNA	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
(	NULL
24	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
JunD	NULL
protein	NULL
is	NULL
a	NULL
very	NULL
stable	NULL
component	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
,	NULL
with	NULL
a	NULL
half-life	NULL
of	NULL
6	NULL
hr	NULL
in	NULL
Swiss	NULL
3T3	NULL
fibroblasts	NULL
(	NULL
34	NULL
)	NULL
.	NULL

JunD	NULL
transactivates	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
in	NULL
a	NULL
cAMP-dependent	NULL
fashion	NULL
and	NULL
specifically	NULL
binds	NULL
CRE-2	NULL
with	NULL
high	NULL
affinity	NULL
as	NULL
a	NULL
homodimer	NULL
.	NULL

Finally	NULL
,	NULL
point	NULL
mutations	NULL
that	NULL
eliminate	NULL
inducible	NULL
enhancer	NULL
function	NULL
in	NULL
vivo	NULL
(	NULL
14	NULL
)	NULL
also	NULL
block	NULL
the	NULL
binding	NULL
of	NULL
JunD	NULL
to	NULL
CRE-2	NULL
.	NULL

Experiments	NULL
using	NULL
in	NULL
vitro	NULL
translated	NULL
JunD	NULL
suggest	NULL
that	NULL
this	NULL
protein	NULL
binds	NULL
to	NULL
CRE-2	NULL
both	NULL
as	NULL
a	NULL
homodimer	NULL
and	NULL
also	NULL
as	NULL
a	NULL
heterodimer	NULL
when	NULL
cotranslated	NULL
with	NULL
c-Fos	NULL
.	NULL

Although	NULL
we	NULL
can	NULL
not	NULL
eliminate	NULL
the	NULL
possibility	NULL
that	NULL
our	NULL
JunD-expressing	NULL
lysates	NULL
also	NULL
express	NULL
c-Fos	NULL
,	NULL
the	NULL
observation	NULL
that	NULL
JunB	NULL
binding	NULL
is	NULL
entirely	NULL
dependent	NULL
on	NULL
c-Fos	NULL
cotranslation	NULL
suggests	NULL
that	NULL
the	NULL
lysates	NULL
contain	NULL
little	NULL
if	NULL
any	NULL
endogenous	NULL
Fos	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
JunD	NULL
binds	NULL
CRE-2	NULL
as	NULL
a	NULL
homodimer	NULL
together	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
c-Fos	NULL
expression	NULL
in	NULL
undifferentiated	NULL
F9	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
suggest	NULL
that	NULL
the	NULL
JunD	NULL
homodimer	NULL
may	NULL
mediate	NULL
the	NULL
PKA-dependent	NULL
activation	NULL
of	NULL
proenkephalin	NULL
transcription	NULL
.	NULL

How	NULL
does	NULL
PKA	NULL
regulate	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
JunD	NULL
?	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
JunD	NULL
is	NULL
a	NULL
phosphoprotein	NULL
(	NULL
34	NULL
)	NULL
.	NULL

It	NULL
is	NULL
unknown	NULL
whether	NULL
it	NULL
can	NULL
be	NULL
phosphorylated	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
by	NULL
PKA	NULL
.	NULL

Unlike	NULL
CREB	NULL
,	NULL
JunD	NULL
does	NULL
not	NULL
contain	NULL
a	NULL
PKA	NULL
consensus	NULL
site	NULL
of	NULL
the	NULL
type	NULL
Arg-Arg-Xaa-Ser	NULL
.	NULL

However	NULL
,	NULL
a	NULL
single	NULL
site	NULL
of	NULL
the	NULL
Lys-Xaa-Xaa-Ser	NULL
type	NULL
is	NULL
present	NULL
that	NULL
is	NULL
not	NULL
present	NULL
in	NULL
the	NULL
closely	NULL
related	NULL
JunB	NULL
molecule	NULL
.	NULL

Alternatively	NULL
,	NULL
PKA	NULL
may	NULL
regulate	NULL
dimerization	NULL
of	NULL
JunD	NULL
with	NULL
itself	NULL
or	NULL
other	NULL
Jun/Fos/CREB-like	NULL
factors	NULL
or	NULL
may	NULL
induce	NULL
expression	NULL
of	NULL
other	NULL
AP-1	NULL
proteins	NULL
,	NULL
which	NULL
,	NULL
like	NULL
Fos	NULL
,	NULL
can	NULL
heterodimerize	NULL
with	NULL
JunD	NULL
.	NULL

Significantly	NULL
,	NULL
cotransfection	NULL
with	NULL
a	NULL
c-Fos-expressing	NULL
plasmid	NULL
has	NULL
little	NULL
or	NULL
no	NULL
effect	NULL
on	NULL
JunD	NULL
transactivation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
PKA	NULL
probably	NULL
does	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

-	NULL
(	NULL
A	NULL
)	NULL
In	NULL
vitro	NULL
translated	NULL
proteins	NULL
.	NULL

[	NULL
**S	NULL
}	NULL
Methionine-labeled	NULL
JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
c-Fos	NULL
translated	NULL
in	NULL
rabbit	NULL
reticulocyte	NULL
lysates	NULL
are	NULL
shown	NULL
.	NULL

Migration	NULL
of	NULL
standards	NULL
of	NULL
known	NULL
molecular	NULL
weight	NULL
are	NULL
indicated	NULL
by	NULL
arrowheads	NULL
(	NULL
M	NULL
,	NULL
x	NULL
(	NULL
B	NULL
)	NULL
Binding	NULL
specificity	NULL
of	NULL
the	NULL
JunD	NULL
homodimer	NULL
.	NULL

One	NULL
microliter	NULL
of	NULL
in	NULL
vitro	NULL
translation	NULL
reaction	NULL
programmed	NULL
either	NULL
without	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
with	NULL
(	NULL
lanes	NULL
2-16	NULL
)	NULL
JunD	NULL
RNA	NULL
was	NULL
incubated	NULL
in	NULL
gel	NULL
mobility-shift	NULL
assays	NULL
with	NULL
radiolabeled	NULL
CRE1+2	NULL
double-stranded	NULL
oligonucleotide	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Unlabeled	NULL
DNA	NULL
competitors	NULL
were	NULL
added	NULL
in	NULL
molar	NULL
excess	NULL
to	NULL
the	NULL
CRE1+2	NULL
probe	NULL
as	NULL
follows	NULL
:	NULL
CRE1+2	NULL
,	NULL
50-fold	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
;	NULL
CRE1+2	NULL
,	NULL
150-fold	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
;	NULL
AP-4	NULL
,	NULL
300-fold	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
;	NULL
AP-2	NULL
(	NULL
GATCCAGC-CCGCCGGCGATTG	NULL
)	NULL
,	NULL
300-fold	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
;	NULL
CRE-1	NULL
,	NULL
300-fold	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
;	NULL
AP-1	NULL
,	NULL
ACCAGCTITGACTCAGATGTCCT	NULL
,	NULL
50-fold	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
;	NULL
AP-1	NULL
,	NULL
150-fold	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
;	NULL
-17	NULL
to	NULL
-27	NULL
of	NULL
the	NULL
rat	NULL
somatostatin	NULL
promoter	NULL
,	NULL
50-fold	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
and	NULL
150-fold	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
;	NULL
CRE-2	NULL
,	NULL
50-fold	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
;	NULL
CRE-2	NULL
,	NULL
150-fold	NULL
(	NULL
lane	NULL
13	NULL
)	NULL
;	NULL
CRE-2	NULL
A-to-T	NULL
with	NULL
substitution	NULL
at	NULL
-86	NULL
,	NULL
150-fold	NULL
(	NULL
lane	NULL
14	NULL
)	NULL
;	NULL
CRE-2	NULL
with	NULL
C-to-T	NULL
substitution	NULL
at	NULL
-87	NULL
,	NULL
150-fold	NULL
(	NULL
lane	NULL
15	NULL
)	NULL
;	NULL
CRE-2	NULL
with	NULL
T-to-A	NULL
substitution	NULL
at	NULL
-88	NULL
,	NULL
150-fold	NULL
(	NULL
lane	NULL
16	NULL
)	NULL
.	NULL

Unless	NULL
otherwise	NULL
indicated	NULL
,	NULL
the	NULL
sequences	NULL
of	NULL
unlabeled	NULL
competitors	NULL
are	NULL
as	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Interactions	NULL
of	NULL
JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
c-Fos	NULL
at	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
.	NULL

Lysates	NULL
containing	NULL
JunD	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
JunB	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
cotranslated	NULL
JunD	NULL
and	NULL
JunB	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
c-Fos	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
cotranslated	NULL
JunD	NULL
and	NULL
c-Fos	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
cotranslated	NULL
JunB	NULL
and	NULL
c-Fos	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
ge	NULL
!	NULL

mobility-shift	NULL
assays	NULL
with	NULL
the	NULL
CRE1+2	NULL
oligonucleotide	NULL
.	NULL

Specific	NULL
protein-DNA	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
arrowhead	NULL
to	NULL
the	NULL
left	NULL
in	NULL
B	NULL
.	NULL

10226	NULL
-	NULL
Neurobiology	NULL
:	NULL
Kobierski	NULL
et	NULL
al	NULL
.	NULL

e	NULL
]	NULL
-	NULL
cz	NULL
FiG	NULL
.	NULL

6	NULL
.	NULL

PKA-dependent	NULL
transactivation	NULL
of	NULL
TRE	NULL
and	NULL
CRE	NULL
DNA	NULL
elements	NULL
.	NULL

F9	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
pENKAT-12	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
pA	NULL
(	NULL
-71	NULL
)	NULL
CAT	NULL
(	NULL
33	NULL
)	NULL
,	NULL
or	NULL
5	NULL
ug	NULL
of	NULL
p-73Col-TRE	NULL
(	NULL
30	NULL
)	NULL
under	NULL
three	NULL
different	NULL
conditions	NULL
:	NULL
control	NULL
,	NULL
no	NULL
cotransfected	NULL
expression	NULL
plasmid	NULL
;	NULL
PKA	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
pMTCaneo	NULL
;	NULL
JunD/PKA	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
pRSVJunD	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
pMTCaneo	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
normalized	NULL
to	NULL
BGal	NULL
expression	NULL
.	NULL

These	NULL
data	NULL
were	NULL
repeated	NULL
several	NULL
times	NULL
.	NULL

not	NULL
act	NULL
simply	NULL
to	NULL
induce	NULL
c-Fos	NULL
in	NULL
F9	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
PKA	NULL
may	NULL
directly	NULL
regulate	NULL
JunD	NULL
DNA	NULL
binding	NULL
,	NULL
as	NULL
has	NULL
been	NULL
recently	NULL
reported	NULL
for	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
c-Jun	NULL
(	NULL
35	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
activating	NULL
proenkephalin	NULL
transcription	NULL
,	NULL
forskolin	NULL
also	NULL
rapidly	NULL
activates	NULL
synthesis	NULL
of	NULL
junB	NULL
and	NULL
c-fos	NULL
mRNA	NULL
in	NULL
C6	NULL
glioma	NULL
cells	NULL
.	NULL

JunB	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
repress	NULL
c-Jun-dependent	NULL
activation	NULL
of	NULL
the	NULL
c-Jun	NULL
promoter	NULL
(	NULL
30	NULL
)	NULL
and	NULL
to	NULL
inhibit	NULL
the	NULL
transforming	NULL
activity	NULL
of	NULL
v-Jun	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Our	NULL
cotransfection	NULL
experiments	NULL
demonstrate	NULL
that	NULL
JunB	NULL
also	NULL
is	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
the	NULL
PKA-dependent	NULL
activation	NULL
of	NULL
proenkephalin	NULL
transcription	NULL
by	NULL
JunD	NULL
and	NULL
suggest	NULL
that	NULL
induction	NULL
of	NULL
JunB	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
protein	NULL
synthesis-dependent	NULL
reduction	NULL
of	NULL
proenkephalin	NULL
mRNA	NULL
that	NULL
is	NULL
apparent	NULL
3-8	NULL
hr	NULL
after	NULL
forskolin	NULL
stimulation	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
rodent	NULL
hippocampal	NULL
granule	NULL
cells	NULL
that	NULL
junD	NULL
mRNA	NULL
is	NULL
constitutively	NULL
expressed	NULL
(	NULL
21	NULL
)	NULL
and	NULL
that	NULL
proenkephalin	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
,	NULL
junB	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
,	NULL
and	NULL
c-fos	NULL
(	NULL
10	NULL
,	NULL
21	NULL
,	NULL
22	NULL
)	NULL
mRNAs	NULL
are	NULL
induced	NULL
after	NULL
electrical	NULL
or	NULL
chemical	NULL
stimulation	NULL
of	NULL
the	NULL
dentate	NULL
gyrus	NULL
.	NULL

These	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
model	NULL
in	NULL
which	NULL
preexisting	NULL
JunD	NULL
would	NULL
mediate	NULL
the	NULL
rapid	NULL
cAMP-dependent	NULL
activation	NULL
of	NULL
the	NULL
proenkephalin	NULL
enhancer	NULL
,	NULL
while	NULL
the	NULL
products	NULL
of	NULL
immediate	NULL
early	NULL
genes	NULL
,	NULL
for	NULL
example	NULL
JunB	NULL
or	NULL
c-Fos	NULL
,	NULL
whose	NULL
messages	NULL
are	NULL
induced	NULL
by	NULL
activation	NULL
of	NULL
second-messenger	NULL
pathways	NULL
would	NULL
be	NULL
involved	NULL
in	NULL
subsequent	NULL
inactivation	NULL
.	NULL

There	NULL
are	NULL
at	NULL
least	NULL
four	NULL
mechanisms	NULL
that	NULL
can	NULL
explain	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
JunB	NULL
on	NULL
the	NULL
PK	NULL
A-dependent	NULL
activation	NULL
of	NULL
proenkephalin	NULL
transcription	NULL
by	NULL
JunD	NULL
.	NULL

(	NULL
#	NULL
)	NULL
JunB	NULL
could	NULL
compete	NULL
with	NULL
JunD	NULL
as	NULL
a	NULL
homodimer	NULL
for	NULL
binding	NULL
to	NULL
CRE-2	NULL
.	NULL

Our	NULL
inability	NULL
to	NULL
detect	NULL
binding	NULL
of	NULL
JunB	NULL
homodimer	NULL
to	NULL
CRE-2	NULL
makes	NULL
this	NULL
possibility	NULL
unlikely	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
JunB	NULL
may	NULL
form	NULL
heterodimers	NULL
with	NULL
JunD	NULL
,	NULL
inhibiting	NULL
the	NULL
ability	NULL
of	NULL
JunD	NULL
to	NULL
bind	NULL
DNA	NULL
or	NULL
to	NULL
activate	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
PKA	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
JunD/JunB	NULL
heterodimers	NULL
form	NULL
in	NULL
vitro	NULL
(	NULL
29	NULL
)	NULL
,	NULL
and	NULL
our	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
JunD/JunB	NULL
cotranslation	NULL
product	NULL
does	NULL
not	NULL
strongly	NULL
inhibit	NULL
DNA	NULL
binding	NULL
.	NULL

(	NULL
i	NULL
?	NULL
)	NULL

JunB	NULL
may	NULL
complex	NULL
with	NULL
a	NULL
protein	NULL
other	NULL
than	NULL
JunD	NULL
and	NULL
compete	NULL
directly	NULL
with	NULL
JunD	NULL
homodimers	NULL
for	NULL
binding	NULL
at	NULL
CRE-2	NULL
.	NULL

Because	NULL
c-fos	NULL
is	NULL
rapidly	NULL
and	NULL
transiently	NULL
coinduced	NULL
with	NULL
junB	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
and	NULL
because	NULL
c-Fos	NULL
stimulates	NULL
binding	NULL
of	NULL
JunB	NULL
to	NULL
CRE-2	NULL
,	NULL
it	NULL
is	NULL
a	NULL
good	NULL
candidate	NULL
.	NULL

This	NULL
mechanism	NULL
seems	NULL
unlikely	NULL
to	NULL
occur	NULL
in	NULL
F9	NULL
cells	NULL
,	NULL
as	NULL
these	NULL
cells	NULL
do	NULL
not	NULL
express	NULL
c-Fos	NULL
.	NULL

We	NULL
can	NULL
not	NULL
,	NULL
however	NULL
,	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
PKA	NULL
acts	NULL
to	NULL
induce	NULL
c-fos	NULL
in	NULL
F9	NULL
cells	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
Jun-B	NULL
may	NULL
act	NULL
to	NULL
inhibit	NULL
JunD-stimulated	NULL
transcription	NULL
by	NULL
competing	NULL
with	NULL
JunD	NULL
for	NULL
a	NULL
required	NULL
``	NULL
'coactivator	NULL
``	NULL
that	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
process	NULL
.	NULL

Although	NULL
much	NULL
attention	NULL
has	NULL
been	NULL
focused	NULL
on	NULL
the	NULL
role	NULL
of	NULL
CREB	NULL
as	NULL
a	NULL
mediator	NULL
of	NULL
cAMP-dependent	NULL
transcriptional	NULL
activation	NULL
,	NULL
our	NULL
results	NULL
demonstrate	NULL
that	NULL
members	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
also	NULL
may	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
both	NULL
activation	NULL
and	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
repression	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
cAMP	NULL
.	NULL

Several	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
AP-1	NULL
proteins	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
binding	NULL
the	NULL
TRE	NULL
or	NULL
AP-1	NULL
site	NULL
,	NULL
also	NULL
bind	NULL
the	NULL
CRE	NULL
with	NULL
equal	NULL
or	NULL
higher	NULL
affinity	NULL
(	NULL
29	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Other	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
TREs	NULL
can	NULL
regulate	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
of	NULL
the	NULL
cAMP-dependent	NULL
pathway	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
our	NULL
findings	NULL
that	NULL
AP-1	NULL
proteins	NULL
also	NULL
mediate	NULL
cAMP-dependent	NULL
gene	NULL
regulation	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
JunD	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
perhaps	NULL
other	NULL
components	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
may	NULL
be	NULL
important	NULL
regulators	NULL
of	NULL
CRE	NULL
as	NULL
well	NULL
as	NULL
TRE	NULL
function	NULL
.	NULL

We	NULL
thank	NULL
Michael	NULL
Uhler	NULL
for	NULL
generously	NULL
supplying	NULL
the	NULL
plasmid	NULL
pMTCaNeo	NULL
,	NULL
Michael	NULL
Greenberg	NULL
for	NULL
a	NULL
plasmid	NULL
encoding	NULL
c-Fos	NULL
,	NULL
and	NULL
Daniel	NULL
Nathans	NULL
for	NULL
plasmids	NULL
encoding	NULL
JunD	NULL
and	NULL
JunB	NULL
.	NULL

We	NULL
thank	NULL
Steven	NULL
Hyman	NULL
and	NULL
Haim	NULL
Rosen	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manu-script	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
Grants	NULL
DAO0S706-01	NULL
and	NULL
DAKO2	NULL
0151	NULL
to	NULL
M.J.C	NULL
.	NULL

1	NULL
.	NULL

Goelet	NULL
,	NULL
P.	NULL
,	NULL
Castellucci	NULL
,	NULL
V.	NULL
F.	NULL
,	NULL
Schacher	NULL
,	NULL
S.	NULL
&	NULL
Kandel	NULL
,	NULL
E.	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
322	NULL
,	NULL
419-422	NULL
.	NULL

Comb	NULL
,	NULL
M.	NULL
,	NULL
Hyman	NULL
,	NULL
S.	NULL
E.	NULL
&	NULL
Goodman	NULL
,	NULL
H.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Trends	NULL
Neurosci	NULL
.	NULL

10	NULL
,	NULL
473-478	NULL
.	NULL

Goodman	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Neurosci	NULL
.	NULL

13	NULL
,	NULL
111-127	NULL
.	NULL

Sheng	NULL
,	NULL
M.	NULL
&	NULL
Greenberg	NULL
,	NULL
M.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
Newron	NULL
4	NULL
,	NULL
477-485	NULL
.	NULL

Morgan	NULL
,	NULL
J.	NULL
I	NULL
.	NULL

&	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Neurosci	NULL
.	NULL

14	NULL
,	NULL
421-451	NULL
.	NULL

Quach	NULL
,	NULL
T.	NULL
T.	NULL
,	NULL
Tang	NULL
,	NULL
F.	NULL
,	NULL
Kageyama	NULL
,	NULL
H.	NULL
,	NULL
Mocchetti	NULL
,	NULL
I.	NULL
,	NULL
Guidotti	NULL
,	NULL
A.	NULL
,	NULL
Meek	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Costa	NULL
,	NULL
E.	NULL
&	NULL
Schwartz	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1984	NULL
)	NULL
Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

26	NULL
,	NULL
255-260	NULL
.	NULL

7	NULL
.	NULL

Kley	NULL
,	NULL
N.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263	NULL
,	NULL
2003-2008	NULL
.	NULL

8	NULL
.	NULL

Fischer-Colbrie	NULL
,	NULL
R.	NULL
,	NULL
lacangelo	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Eiden	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
3240-3244	NULL
.	NULL

9	NULL
.	NULL

Morris	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Feasey	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Ten	NULL
Bruggencate	NULL
,	NULL
G.	NULL
,	NULL
Herz	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Holit	NULL
,	NULL
V.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
3226-3230	NULL
.	NULL

10	NULL
.	NULL

White	NULL
,	NULL
J.	NULL
D.	NULL
&	NULL
Gall	NULL
,	NULL
C.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Brain	NULL
Res	NULL
.	NULL

3	NULL
,	NULL
21-29	NULL
.	NULL

11	NULL
.	NULL

Yoshikawa	NULL
,	NULL
K.	NULL
&	NULL
Sabol	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1986	NULL
)	NULL
Mol	NULL
.	NULL

Brain	NULL
Res	NULL
.	NULL

1	NULL
,	NULL
75-83	NULL
.	NULL

12	NULL
.	NULL

Sonnenberg	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Rauscher	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Morgan	NULL
,	NULL
J.	NULL
I	NULL
.	NULL

&	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1622-1625	NULL
.	NULL

13	NULL
.	NULL

Comb	NULL
,	NULL
M.	NULL
,	NULL
Birnberg	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Seasholtz	NULL
,	NULL
A.	NULL
,	NULL
Herbert	NULL
,	NULL
E.	NULL
&	NULL
Goodman	NULL
,	NULL
H.	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
323	NULL
,	NULL
353-356	NULL
.	NULL

14	NULL
.	NULL

Comb	NULL
,	NULL
M.	NULL
,	NULL
Mermond	NULL
,	NULL
N.	NULL
,	NULL
Hyman	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Pearliberg	NULL
,	NULL
J.	NULL
,	NULL
Ross	NULL
,	NULL
M.	NULL
E.	NULL
&	NULL
Goodman	NULL
,	NULL
H.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
3793-3805	NULL
.	NULL

15	NULL
.	NULL

Hyman	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Comb	NULL
,	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
Y.-S.	NULL
,	NULL
Peariberg	NULL
,	NULL
J.	NULL
,	NULL
Green	NULL
,	NULL
M.	NULL
R.	NULL
&	NULL
Goodman	NULL
,	NULL
H.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
4225-4233	NULL
.	NULL

16	NULL
.	NULL

Nguyen	NULL
,	NULL
T.	NULL
V.	NULL
,	NULL
Kobierski	NULL
,	NULL
L.	NULL
,	NULL
Comb	NULL
,	NULL
M.	NULL
&	NULL
Hyman	NULL
,	NULL
S.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Neurosci	NULL
.	NULL

10	NULL
,	NULL
2825-2833	NULL
.	NULL

17	NULL
.	NULL

Meinkoth	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Ji	NULL
,	NULL
Y.	NULL
,	NULL
Taylor	NULL
,	NULL
S.	NULL
S.	NULL
&	NULL
Feramisco	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
,	NULL
9595-9599	NULL
.	NULL

18	NULL
.	NULL

Gonzalez	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

&	NULL
Montminy	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
675-680	NULL
.	NULL

19	NULL
.	NULL

Montminy	NULL
,	NULL
M.	NULL
R.	NULL
&	NULL
Bilezikjian	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
328	NULL
,	NULL
175-178	NULL
.	NULL

20	NULL
.	NULL

Lee	NULL
,	NULL
C.	NULL
Q.	NULL
,	NULL
Yun	NULL
,	NULL
Y.	NULL
,	NULL
Hoeffler	NULL
,	NULL
J.	NULL
P.	NULL
&	NULL
Habener	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
4455-4465	NULL
.	NULL

21	NULL
.	NULL

Wisden	NULL
,	NULL
W.	NULL
,	NULL
Errington	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Williams	NULL
,	NULL
S.	NULL
,	NULL
Dunnett	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Waters	NULL
,	NULL
C.	NULL
,	NULL
Hitchcock	NULL
,	NULL
D.	NULL
,	NULL
Evan	NULL
,	NULL
G.	NULL
,	NULL
Bliss	NULL
,	NULL
T.	NULL
V.	NULL
P.	NULL
&	NULL
Hunt	NULL
,	NULL
S.	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Neuron	NULL
4	NULL
,	NULL
603-614	NULL
.	NULL

22	NULL
.	NULL

Saffen	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Cole	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Worley	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Christy	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Ryder	NULL
,	NULL
K.	NULL
&	NULL
Baraban	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
8§	NULL
,	NULL
7795-7799	NULL
.	NULL

23	NULL
.	NULL

Hoeffler	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Deutsch	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Lin	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Habener	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

3	NULL
,	NULL
868-880	NULL
.	NULL

24	NULL
.	NULL

Ryder	NULL
,	NULL
K.	NULL
,	NULL
Lanahan	NULL
,	NULL
A.	NULL
,	NULL
Perez-Albuerne	NULL
,	NULL
E.	NULL
&	NULL
Nathans	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
1500-1503	NULL
.	NULL

25	NULL
.	NULL

Ryder	NULL
,	NULL
K.	NULL
,	NULL
Lau	NULL
,	NULL
L.	NULL
F.	NULL
&	NULL
Nathans	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
1487-1491	NULL
.	NULL

26	NULL
.	NULL

Sassone-Corsi	NULL
,	NULL
P.	NULL
,	NULL
Lamph	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Kamps	NULL
,	NULL
M.	NULL
&	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
54	NULL
,	NULL
553-560	NULL
.	NULL

27	NULL
.	NULL

Huggenvik	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
Collard	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Stofko	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Seasholtz	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Uhler	NULL
,	NULL
M.	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

5	NULL
,	NULL
921-930	NULL
.	NULL

28	NULL
.	NULL

Edlund	NULL
,	NULL
T.	NULL
,	NULL
Walker	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Barr	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

&	NULL
Rutter	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Science	NULL
230	NULL
,	NULL
912-916	NULL
.	NULL

29	NULL
.	NULL

Nakabeppu	NULL
,	NULL
Y.	NULL
,	NULL
Ryder	NULL
,	NULL
K.	NULL
&	NULL
Nathans	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
907-915	NULL
.	NULL

30	NULL
.	NULL

Chiu	NULL
,	NULL
R.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
979-986	NULL
.	NULL

31	NULL
.	NULL

Ryseck	NULL
,	NULL
R.-P.	NULL
&	NULL
Bravo	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
533-542	NULL
.	NULL

32	NULL
.	NULL

Montminy	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Sevarino	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Wagner	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Mandel	NULL
,	NULL
G.	NULL
&	NULL
Goodman	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83	NULL
,	NULL
6682-6686	NULL
.	NULL

33	NULL
.	NULL

Hirai	NULL
,	NULL
S.-I	NULL
.	NULL

,	NULL
Ryseck	NULL
,	NULL
R.-P.	NULL
,	NULL
Mechta	NULL
,	NULL
F.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
&	NULL
Yaniv	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
1433-1439	NULL
.	NULL

34	NULL
.	NULL

Kovary	NULL
,	NULL
K.	NULL
&	NULL
Bravo	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
2451-2459	NULL
.	NULL

35	NULL
.	NULL

Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Defize	NULL
,	NULL
L.	NULL
H.	NULL
K.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Woodgett	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
&	NULL
Hunter	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
573-584	NULL
.	NULL

36	NULL
.	NULL

-	NULL
Schutte	NULL
,	NULL
J.	NULL
,	NULL
Viallet	NULL
,	NULL
J.	NULL
,	NULL
Nau	NULL
,	NULL
M.	NULL
,	NULL
Segal	NULL
,	NULL
S.	NULL
,	NULL
Fedorko	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Minna	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
987-997	NULL
.	NULL

Lind	NULL
a	NULL
i	NULL
e	NULL

